INVESTOR ALERT: Investigation of Savara Inc. (SVRA) Announced by Holzer & Holzer, LLC

Core Points - Savara Inc. received a refusal to file letter from the FDA regarding its Biologics License Application for MOLBREEVI, intended for treating autoimmune pulmonary alveolar proteinosis [1] - Following the FDA's decision, Savara's stock price experienced a decline [1] Company Information - Holzer & Holzer, LLC is investigating whether Savara complied with federal securities laws in light of the recent FDA decision [1] - The law firm specializes in representing shareholders and investors in litigation, including class action and derivative litigation, and has recovered hundreds of millions of dollars for affected shareholders since its founding in 2000 [3]